10-Q: Hepion Pivots to Diagnostics Amid Delisting & Losses

Hepion Pharmaceuticals shifts from drug development to diagnostics after clinical trial wind-down and failed merger, securing new licenses while navigating Nasdaq delisting and persistent financial challenges.

Summary

• Hepion Pharmaceuticals has transitioned from a drug development company, previously focused on chronic liver diseases with rencofilstat, to a medical diagnostic company.
• The ASCEND-NASH clinical trial for rencofilstat was wound down starting April 19, 2024, and closed in August 2024, due to insufficient funding.
• A merger agreement with Pharma Two B Ltd., entered on July 19, 2024, was terminated on December 10, 2024, as Nasdaq would not exclude Hepion's historical losses from its burn rate calculation.
• On May 9, 2025, Hepion in-licensed diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori), and hepatocellular carcinoma (HCC) from New Day Diagnostics LLC.
• The company paid $525,000 in cash and $270,629 in common stock for the New Day Diagnostics license, with potential future milestone payments up to $17.15 million and royalties.
• An asset impairment loss of $402,746 was recorded for the newly licensed diagnostic assets due to delayed timing to market and insufficient projected cash flow to recover costs within the initial two-year license term.
• On May 26, 2025, Hepion sold all Rencofilstat-related patent assets, know-how, clinical trial data, and drug product to Panetta Partners Limited for a nominal amount, transferring contingent consideration obligations and receiving contingent value rights (CVRs) tied to future Rencofilstat milestones.
• The company completed a public offering on January 23, 2025, raising approximately $9.0 million in gross proceeds from the sale of common stock and Series A and B warrants, which was used to repay $2.9 million in notes payable and for general corporate purposes.
• A one-for-fifty reverse stock split was effected on March 17, 2025.
• Hepion was delisted from Nasdaq on May 13, 2025, due to failure to meet listing standards (bid price below $0.10 and being deemed a public shell), and subsequently transitioned to the OTCQB Venture Market on June 25, 2025.
• As of June 30, 2025, cash stood at $2,924,395, a significant increase from $406,408 at December 31, 2024.
• Working capital improved to $3.9 million as of June 30, 2025, from a deficit of $1.5 million at December 31, 2024.
• Net loss for the six months ended June 30, 2025, was $(7,148,459), compared to $(6,779,018) for the same period in 2024.
• Research and development expenses decreased significantly to $445,512 for the six months ended June 30, 2025, from $9,676,247 in the prior year period, primarily due to the discontinuation of clinical trials.
• General and administrative expenses also decreased to $2,177,848 from $4,009,918 year-over-year.
• The company continues to have substantial doubt about its ability to continue as a going concern without additional capital.
• Material weaknesses in internal control over financial reporting were identified, including insufficient personnel, lack of segregation of duties, and inadequate controls over complex accounting transactions and income tax provision.

Sentiment

Score: 2

Explanation: The company has undergone a complete strategic pivot, abandoning its core drug development program due to funding issues and selling its assets for a nominal amount. It failed to complete a merger and was subsequently delisted from Nasdaq, moving to a less liquid market. While it raised capital and improved its cash position and working capital, the impairment of its newly acquired diagnostic assets and the persistent "going concern" warning indicate severe underlying financial instability and significant operational challenges. The identified material weaknesses in internal controls further compound the negative outlook.

Positives

• Cash balance increased significantly to $2,924,395 as of June 30, 2025, from $406,408 at December 31, 2024.
• Working capital improved to $3.9 million as of June 30, 2025, from a deficit of $1.5 million at December 31, 2024.
• Net cash used in operating activities decreased substantially to $2,492,782 for the six months ended June 30, 2025, from $14,545,497 in the prior year period, indicating a reduced cash burn rate from operations.
• Research and development expenses decreased by $9.3 million for the six months ended June 30, 2025, primarily due to the discontinuation of costly clinical trials.
• General and administrative expenses decreased by $1.8 million for the six months ended June 30, 2025, due to reduced headcount and other cost-saving measures.
• Successful capital raise of $9.0 million gross proceeds in January 2025, which helped repay existing debt.
• Successful transition to the OTCQB Venture Market after Nasdaq delisting, maintaining public trading.

Negatives

• Net loss increased to $(7,148,459) for the six months ended June 30, 2025, compared to $(6,779,018) for the same period in 2024.
• Incurred an asset impairment loss of $402,746 related to the newly licensed diagnostic assets, indicating challenges in immediate commercialization or recovery of costs.
• Significant negative change in fair value of derivative financial instruments of $(4,102,408) for the six months ended June 30, 2025.
• Accumulated deficit increased to $(244,968,265) as of June 30, 2025.
• The company has not generated any revenue to date and expects to continue incurring significant losses.
• The primary drug development program (rencofilstat) was discontinued due to insufficient funding, and the related assets were sold for a nominal amount.
• A planned merger with Pharma Two B Ltd. was terminated due to Nasdaq's refusal to exclude historical losses from burn rate calculations.
• Delisted from Nasdaq and moved to the OTCQB Venture Market, which typically implies lower liquidity and investor visibility.
• Substantial doubt exists about the company's ability to continue as a going concern without additional capital.
• Identified material weaknesses in internal control over financial reporting, including insufficient personnel, lack of segregation of duties, and inadequate controls over complex accounting and income tax provisions.

Risks

• Ability to raise substantial additional capital to continue as a going concern and fund planned operations in the near term.
• Uncertainties regarding estimates of expenses, use of cash, timing of future cash needs, and anticipated capital requirements.
• Success in retaining, or changes required in, officers, key employees, or directors.
• Potential liquidity and trading issues for public securities, especially after delisting from Nasdaq.
• Ability to obtain and maintain regulatory approval of product candidates, and any related restrictions, limitations, or warnings.
• Plans to pursue research and development of other future product candidates.
• Potential advantages of product candidates and those being developed.
• Rate and degree of market acceptance and clinical utility of product candidates.
• Success of collaborations and partnerships with third parties.
• Estimates regarding the potential market opportunity for product candidates.
• Sales, marketing, and distribution capabilities and strategy.
• Ability to establish and maintain arrangements for manufacture of product candidates.
• Ability to compete with companies currently marketing or engaged in the development of treatments for targeted indications.
• Intellectual property position, including the strength and enforceability of intellectual property rights.
• Risk of not being able to remediate identified material weaknesses in internal control over financial reporting in a timely manner.
• The contingent value rights (CVRs) from the Rencofilstat sale have a high uncertainty of achieving milestones.
• The licensed diagnostic assets may not generate sufficient cash flow to recover their allocated cost within the initial two-year license agreement term, as evidenced by the impairment loss.

Future Outlook

The company expects to continue incurring significant losses for the foreseeable future as it develops acquired diagnostic assets. Future capital requirements depend on the scope, progress, results, and costs of developing product candidates, obtaining regulatory approvals, establishing sales and marketing, manufacturing, collaborations, and intellectual property costs. The company will require additional financing to continue operations and may need to curtail planned operations or seek less favorable terms if funds are not available.

Management Comments

• We believe that it is important to communicate future expectations to investors. However, there may be events in the future that we are not able to accurately predict or control.
• We are committed to the remediation of the material weaknesses described above, as well as the continued improvement of our internal control over financial reporting.
• We need to raise additional capital in order to add additional personnel and implement additional internal control procedures.
• If we are able to raise additional capital, we plan on implementing several remedial actions to improve our internal controls.

Industry Context

Hepion's pivot from drug development, particularly in chronic liver diseases like NASH, to medical diagnostics represents a significant strategic shift. The discontinuation of its lead drug candidate, rencofilstat, and the sale of its related assets for a nominal amount, signals a complete exit from its prior core business. The move into diagnostics, specifically for celiac disease, respiratory multiplex, H. pylori, and HCC, positions the company in a different segment of the healthcare industry. While some of these diagnostic tests have CE marks for European markets, the immediate impairment loss on these assets suggests challenges in their commercial viability or market entry, indicating a difficult transition. This pivot is likely a survival strategy given the funding challenges and failed merger in its previous domain, but it places Hepion in a highly competitive diagnostics market with established players.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results within the diagnostic industry to benchmark Hepion's new licensed assets against.
• The impairment loss of $402,746 on the newly acquired diagnostic assets, due to projected cash flows not being enough to recover allocated costs in the first two years, suggests that the immediate commercial prospects for these assets are below typical industry expectations for new product acquisitions.
• The company's continued reliance on external financing and its "going concern" warning are significantly below industry standards for established, revenue-generating diagnostic companies.

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings, but management believes the outcome will not have a material adverse effect on consolidated financial condition or results of operations.

Stakeholder Impact

• Shareholders: Experienced significant dilution from past equity issuances and potential future dilution from additional capital raises. Affected by the one-for-fifty reverse stock split. Impacted by the Nasdaq delisting and transition to OTCQB, potentially leading to reduced liquidity and investor visibility. The sale of Rencofilstat assets for a nominal amount and the high uncertainty of CVRs may negatively impact long-term value from the previous drug development focus.
• Employees: Reduced headcounts mentioned as a reason for decreased employee compensation costs, indicating potential layoffs or restructuring.
• Customers: Potential future customers for diagnostic tests in the EU and other eligible markets, but no current commercial products or revenue.
• Creditors: Notes payable of $2.9 million were repaid using proceeds from the January 2025 public offering.
• Regulatory Authorities: Nasdaq delisted the company due to listing standard failures, including being deemed a public shell.

Next Steps

• Raise additional capital to continue funding operations.
• Implement remedial actions to improve internal controls, including increasing personnel for segregation of duties, utilizing external consultants for complex accounting, expanding review processes, and enhancing tax provision procedures.
• Develop and commercialize the in-licensed diagnostic tests, aiming to generate revenue from sales in the European Union and other eligible markets.
• Potentially achieve regulatory, sales, and reimbursement milestones for the diagnostic tests, triggering payments to New Day Diagnostics.
• Potentially achieve milestones for Rencofilstat under the CVR agreement with Panetta Partners Limited.

Key Dates

Recommendation

The company has undergone a drastic strategic shift, abandoning its core drug development business due to funding failures and selling its primary asset for a nominal sum. It has been delisted from Nasdaq, indicating severe governance and financial health issues, and now trades on a less liquid market. Despite a recent capital raise, the company explicitly states "substantial doubt" about its ability to continue as a going concern and has identified material weaknesses in its internal controls. The impairment loss on its newly acquired diagnostic assets further highlights the challenges in its new business direction. These factors collectively point to significant operational and financial distress, making the stock a high-risk, speculative investment with a strong likelihood of further value erosion.

Keywords

Medical Diagnostics, Biotechnology, SEC Filing, 10-Q, Financial Report, Going Concern, Capital Raise, Nasdaq Delisting, OTCQB, Warrants, Reverse Stock Split, Internal Controls, Celiac Disease, Respiratory Diagnostics, H. pylori, Hepatocellular Carcinoma